Edition:
United Kingdom

Merck Says Phase 3 Study Of Keytruda Monotherapy In Triple-Negative Breast Cancer Did Not Meet Primary Endpoint Of Superior Overall Survival


Monday, 20 May 2019 

May 20 (Reuters) - Merck & Co Inc ::MERCK PROVIDES UPDATE ON PHASE 3 KEYNOTE-119 STUDY OF KEYTRUDA® (PEMBROLIZUMAB) MONOTHERAPY IN PREVIOUSLY-TREATED PATIENTS WITH METASTATIC TRIPLE-NEGATIVE BREAST CANCER.MERCK PROVIDES UPDATE ON PHASE 3 KEYNOTE-119 STUDY OF KEYTRUDA® (PEMBROLIZUMAB) MONOTHERAPY IN PREVIOUSLY-TREATED PATIENTS WITH METASTATIC TRIPLE-NEGATIVE BREAST CANCER.MERCK & CO INC - PHASE 3 KEYNOTE-119 STUDY OF KEYTRUDA(® MONOTHERAPY DID NOT MEET ITS PRE-SPECIFIED PRIMARY ENDPOINT OF SUPERIOR OVERALL SURVIVAL.MERCK & CO INC - OTHER ENDPOINTS WERE NOT FORMALLY TESTED PER STUDY PROTOCOL BECAUSE PRIMARY ENDPOINT OF OS WAS NOT MET.MERCK & CO INC - SAFETY PROFILE OF KEYTRUDA IN THIS TRIAL WAS CONSISTENT WITH THAT OBSERVED IN PREVIOUSLY REPORTED STUDIES.MERCK & CO INC - NO NEW SAFETY CONCERNS WERE IDENTIFIED IN STUDY.